Related Experiment Video

Updated: May 9, 2026

Analysis of SCAP N-glycosylation and Trafficking in Human Cells
11:27

Analysis of SCAP N-glycosylation and Trafficking in Human Cells

Published on: November 8, 2016

Targeting SREBP-1-driven lipid metabolism to treat cancer

Deliang Guo, Erica Hlavin Bell, Paul Mischel

  • 1Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center and Arthur G. James Cancer Hospital, Columbus, OH 43210, USA. deliang.guo@osumc.edu.

Current Pharmaceutical Design
|July 18, 2013
PubMed

Insights

Cancer cells reprogram metabolism for growth. Sterol regulatory element-binding protein 1 (SREBP-1) links oncogenic signaling to lipid metabolism, crucial for glioblastoma survival and potentially other cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Metabolic Pathways

Background:

  • Metabolic reprogramming is a key characteristic of cancer, supporting tumor cell proliferation.
  • Oncogenic signaling pathways alter glucose, glutamine, and lipid metabolism to meet cellular demands.
  • Sterol regulatory element-binding protein 1 (SREBP-1) is emerging as a central regulator of lipid metabolism in cancer.

Purpose of the Study:

  • To elucidate the role of SREBP-1 in linking oncogenic signaling to cancer metabolism.
  • To investigate the EGFR/PI3K/Akt/SREBP-1 signaling pathway in glioblastoma.
  • To explore SREBP-1's connections with glycolysis and glutaminolysis in cancer.

Main Methods:

  • Review of recent insights into cancer lipid metabolism.
  • Analysis of evidence linking SREBP-1 to PI3K/Akt and Myc signaling.
  • Discussion of potential therapeutic strategies targeting SREBP-1.

Main Results:

  • SREBP-1 is essential for the survival of glioblastoma with mutant EGFR.
  • SREBP-1 upregulates fatty acid synthesis and LDL receptor (LDLR) expression, supporting tumor cell survival.
  • The EGFR/PI3K/Akt/SREBP-1 pathway promotes glioblastoma growth and survival.

Conclusions:

  • SREBP-1 is a critical mediator of oncogenic signaling in cancer metabolism.
  • Targeting SREBP-1-driven lipid metabolism presents a potential therapeutic avenue for cancer treatment.
  • Further research into SREBP-1's role in linking various metabolic pathways is warranted.

More Related Videos

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes: